Publication
Undertaking to maintain status quo pending “determination”
Interlocutory injunctions routinely raise a similar issue – how are the parties to conduct themselves in the period prior to the injunction hearing?
Global | Publication | May 2017
Treaty/Act: CETA/Bill C-30 (An Act to implement the Comprehensive Economic and Trade Agreement between Canada and the European Union and its Member States and to provide for certain other measures)
Date: May 11, 2017 – Bill C-30 passes third reading in Senate
The overhaul to Canada’s pharmaceutical patent regime is nearly here. On May 11, 2017, the Canadian Senate passed Bill C-30 (the act intended to implement CETA into Canadian law) without amendment, the final major stage of the legislative process. Bill C-30 will become law once it receives royal assent, a formality.
As we reported, CETA and Bill C-30 provide key reforms to the Patent Act affecting the pharmaceutical industry, including:
We anticipate the details to be published shortly.
Are you CETA ready? Contact Norton Rose Fulbright with all your CETA questions.
Bill C-30, Third Reading (House of Commons)
Text of the final Comprehensive Economic and Trade Agreement
Publication
Interlocutory injunctions routinely raise a similar issue – how are the parties to conduct themselves in the period prior to the injunction hearing?
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023